Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2018-04-05 Capital/Financing Update
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Cleansing Notice 1 page 124.3KB
Capital/Financing Update Classification · 95% confidence The document is a Cleansing Notice issued under section 708A(5)(e) of the Corporations Act 2001 (Cth). It relates to the issuance of shares without disclosure under Part 6D.2 of the Corporations Act and confirms compliance with relevant provisions. The content is about a capital raising event and legal compliance notice rather than a full financial report or earnings release. It is not an Annual Report, Interim Report, or Earnings Release. It is also not a report publication announcement or certification. The document fits the category of Capital/Financing Update (CAP) as it provides an update on the company's fundraising activity and share issuance.
2018-04-05 English
Letters to Shareholders and Optionholders 3 pages 70.4KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated April 2018 from Antisense Therapeutics Limited regarding a non-renounceable entitlement offer to raise approximately $4.5 million. It details the terms of the offer, including the offer price, ratio, record date, and timetable for the offer. It also includes instructions for option holders on how to participate by exercising options before the record date. The document is primarily focused on informing shareholders and option holders about the capital raising event and the procedural details of the entitlement offer. There are no financial statements, management discussion, or detailed financial results included. The document is not a full financial report, earnings release, or regulatory certification. It is a capital raising update and offer announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6270 characters) and content support this classification with high confidence.
2018-04-05 English
Letter to Optionholders 1 page 76.8KB
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to option holders regarding a non-renounceable entitlement offer announced by the company. It explains the terms under which option holders can exercise their options to participate in the entitlement offer. The content focuses on capital raising activity and instructions related to exercising options for share issuance. There are no financial statements, detailed financial analysis, or regulatory certifications present. The document is short (1999 characters) and serves as an announcement or update about a financing event rather than a full report or detailed financial disclosure. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2018-04-05 English
Institutional Placement and Rights Issue 2 pages 235.8KB
Capital/Financing Update Classification · 95% confidence The document is an announcement detailing a capital raising event involving an institutional placement and a rights issue to raise funds for clinical trials and operations. It discusses the specifics of the placement, the investors involved, the use of proceeds, and upcoming clinical trial plans. There are no financial statements or detailed financial performance data presented. The document focuses on financing activities and capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive content about the capital raising, not just a brief notice or report publication announcement.
2018-04-02 English
Trading Halt 2 pages 754.6KB
Capital/Financing Update Classification · 95% confidence The document is a market release announcing a trading halt for Antisense Therapeutics Limited. It references ASX Listing Rule 17.1 and states the halt is pending an institutional placement and entitlement issue. The document is short (2069 characters) and is an announcement about a trading halt, not a financial report or detailed update. This fits the category of Capital/Financing Update (CAP) because it relates to fundraising activities and capital structure changes, specifically an institutional placement and entitlement issue. It is not a report itself, nor a regulatory filing or announcement of a report publication. Therefore, the correct classification is CAP with high confidence.
2018-03-27 English
Half Year Accounts Appendix 4D 25 pages 499.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Antisense Therapeutics Limited Appendix 4D For the Half-year ended 31 December 2017' and contains detailed financial results, including revenues, loss after tax, net tangible assets per share, and earnings per share for the half-year period ending 31 December 2017. It includes a Directors' report, review of operations, and detailed descriptions of clinical development projects. The document also references an auditor's review report and financial statements such as the statement of profit or loss, statement of financial position, and notes to the financial statements. The length is substantial (15,000 characters), and it contains actual financial data and analysis for a half-year period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data and analysis. The document is not merely an announcement or a certification, but a full interim financial report with operational and financial details. H1 2018
2018-02-27 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.